Evidence map›Paper›PMID 39096403›Full record

ArticleBreast cancer research and treatment2024

Fragmentation of care in breast cancer: greater than the sum of its parts.

Hadley D Freeman, Linnea C Burke, Ja'Neil G Humphrey, Ashley J Wilbers, Halley Vora, Rhami Khorfan, Naveenraj L Solomon, Jukes P Namm, Liang Ji, Sharon S Lum

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hadley D FreemanDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Linnea C BurkeDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Ja'Neil G HumphreyDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Ashley J WilbersDivision of Breast Surgery, Department of Surgery, Washington University, St. Louis, MO, USA.
Halley VoraDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Rhami KhorfanDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Naveenraj L SolomonDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Jukes P NammDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Liang JiDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Sharon S LumDivision of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA. slum@llu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFragmentation of care (FC, the receipt of care at > 1 institution) has been shown to negatively impact cancer outcomes. Given the multimodal nature of breast cancer treatment, we sought to identify factors associated with FC and its effects on survival of breast cancer patients.

methodsA retrospective analysis was performed of surgically treated, stage I-III breast cancer patients in the 2004-2020 National Cancer Database, excluding neoadjuvant therapy recipients. Patients were stratified into two groups: FC or non-FC care. Treatment delay was defined as definitive surgery > 60 days after diagnosis. Multivariable logistic regression was performed to identify factors predictive of FC, and survival was compared using Kaplan-Meier and multivariable Cox proportional hazards methods.

resultsOf the 531,644 patients identified, 340,297 (64.0%) received FC. After adjustment, FC (OR 1.27, 95% CI 1.25-1.29) was independently associated with treatment delay. Factors predictive of FC included Hispanic ethnicity (OR 1.04, 95% CI: 1.01-1.07), treatment at comprehensive community cancer programs (OR 1.06, 95% CI: 1.03-1.08) and integrated network cancer programs (OR 1.55, 95% CI: 1.51-1.59), AJCC stage II (OR 1.06, 95% CI 1.05-1.07) and stage III tumors (OR 1.06, 95% CI: 1.02-1.10), and HR + /HER2 + tumors (OR 1.05, 95% CI: 1.02-1.07). Treatment delay was independently associated with increased risk of mortality (HR 1.23, 95% CI 1.20-1.26), whereas FC (HR 0.87, 95% CI 0.86-0.88) showed survival benefit.

conclusionsWhile treatment delay negatively impacts survival in breast cancer patients, our findings suggest FC could be a marker for multispecialty care that may mitigate some of these effects.

Indexed as

Breast NeoplasmsNeoplasm StagingAdultAgedFemaleHumansKaplan-Meier EstimateMiddle AgedRetrospective StudiesTime-to-TreatmentBreast CancerCare FragmentationMulti-institutional CareSurvival

Identifiers

PMID39096403
PMCPMC11522034

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.